ID
17654
Description
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Tarceva Consent and Eligibility
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Keywords
Versions (2)
- 8/2/16 8/2/16 -
- 9/27/16 9/27/16 -
Uploaded on
September 27, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425
Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
Description
Open-label Tarceva Eligibility
Description
Open-label Tarceva Eligibility
Data type
boolean
Alias
- UMLS CUI [1]
- C1516637
Description
Eligibility Criteria: OSI-774-302 Protocol Version 2, 21 November 2007, Appendix 12.9
Data type
boolean
Alias
- UMLS CUI [1]
- C1302261
Description
Eligibility Criteria
Data type
boolean
Alias
- UMLS CUI [1]
- C1516637
Description
Eligibility Criteria
Data type
boolean
Alias
- UMLS CUI [1]
- C1516637
Description
Eligibility Criteria
Data type
boolean
Alias
- UMLS CUI [1]
- C1516637
Description
Eligibility Criteria
Data type
boolean
Alias
- UMLS CUI [1]
- C1516637
Description
Exemption
Data type
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Description
Investigator Signature
Description
I have reviewed all data for this patient's eligibility and confirm that consent has been obtained in accordance with the GCP Directive (2005/28/EC) or EU Directive (2001/20/EC) and other applicable GCP requirements.
Data type
text
Alias
- UMLS CUI [1]
- C2346576
Description
Investigator Signature Date
Data type
date
Alias
- UMLS CUI [1,1]
- C2346576
- UMLS CUI [1,2]
- C0011008
Similar models
Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425
C1135136 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])